Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma

This study has been completed.
Information provided by (Responsible Party):
GlaxoSmithKline Identifier:
First received: January 10, 2013
Last updated: November 9, 2015
Last verified: November 2015
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: September 2015
  Primary Completion Date: September 2015 (Final data collection date for primary outcome measure)
No publications provided by GlaxoSmithKline

Publications automatically indexed to this study by Identifier (NCT Number):